DC-based vaccines gaining ground

Tampa, Fla. — Although development of melanoma vaccines based on dendritic cells (DCs) lags behind that of more established approaches, it's rapidly moving from the lab bench into clinical trials.

Related Videos
Related Content

Risankizumab Efficacious in Patients with Prior Plaque Psoriasis Biologic Use

March 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Roflumilast Safe and Efficient for Patients with Chronic Plaque Psoriasis

March 22nd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023

Phase 3 Data for Bimekizumab Shows Well Maintained Response

March 21st 2023

Risankizumab Efficacious in Patients with Prior Plaque Psoriasis Biologic Use

March 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Roflumilast Safe and Efficient for Patients with Chronic Plaque Psoriasis

March 22nd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023

Phase 3 Data for Bimekizumab Shows Well Maintained Response

March 21st 2023

Risankizumab Efficacious in Patients with Prior Plaque Psoriasis Biologic Use

March 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Roflumilast Safe and Efficient for Patients with Chronic Plaque Psoriasis

March 22nd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023

Phase 3 Data for Bimekizumab Shows Well Maintained Response

March 21st 2023
© 2023 MJH Life Sciences

All rights reserved.